Transfer function analysis of dynamic cerebral autoregulation: A CARNet white paper 2022 update

Cerebral autoregulation (CA) refers to the control of cerebral tissue blood flow (CBF) in response to changes in perfusion pressure. Due to the challenges of measuring intracranial pressure, CA is often described as the relationship between mean arterial pressure (MAP) and CBF. Dynamic CA (dCA) can...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of cerebral blood flow and metabolism Ročník 43; číslo 1; s. 3
Hlavní autoři: Panerai, Ronney B, Brassard, Patrice, Burma, Joel S, Castro, Pedro, Claassen, Jurgen Ahr, van Lieshout, Johannes J, Liu, Jia, Lucas, Samuel Je, Minhas, Jatinder S, Mitsis, Georgios D, Nogueira, Ricardo C, Ogoh, Shigehiko, Payne, Stephen J, Rickards, Caroline A, Robertson, Andrew D, Rodrigues, Gabriel D, Smirl, Jonathan D, Simpson, David M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.01.2023
Témata:
Brain - blood supply
Reproducibility of Results
reference values
transfer function analysis
Cerebral hemodynamics
consensus guidelines
ISSN:1559-7016, 1559-7016
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cerebral autoregulation (CA) refers to the control of cerebral tissue blood flow (CBF) in response to changes in perfusion pressure. Due to the challenges of measuring intracranial pressure, CA is often described as the relationship between mean arterial pressure (MAP) and CBF. Dynamic CA (dCA) can be assessed using multiple techniques, with transfer function analysis (TFA) being the most common. A 2016 white paper by members of an international Cerebrovascular Research Network (CARNet) that is focused on CA strove to improve TFA standardization by way of introducing data acquisition, analysis, and reporting guidelines. Since then, additional evidence has allowed for the improvement and refinement of the original recommendations, as well as for the inclusion of new guidelines to reflect recent advances in the field. This second edition of the white paper contains more robust, evidence-based recommendations, which have been expanded to address current streams of inquiry, including optimizing MAP variability, acquiring CBF estimates from alternative methods, estimating alternative dCA metrics, and incorporating dCA quantification into clinical trials. Implementation of these new and revised recommendations is important to improve the reliability and reproducibility of dCA studies, and to facilitate inter-institutional collaboration and the comparison of results between studies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1559-7016
1559-7016
DOI:10.1177/0271678X221119760